https://www.nexuspharmalink.com/blogRSS for NodeSun, 05 Apr 2026 09:19:38 GMThttps://www.nexuspharmalink.com/en/post/gcc-vs-maghreb-why-treating-mena-as-a-single-market-is-the-most-expensive-mistake-in-pharma-bd69c1943e0bafcf3586192ebdMon, 23 Mar 2026 19:32:13 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/ccg-vs-maghreb-pourquoi-traiter-le-mena-comme-un-march%C3%A9-unique-est-l-erreur-la-plus-co%C3%BBteuse-du-b69c1923b8f0e652aaa2c4816Mon, 23 Mar 2026 19:27:40 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/pourquoi-la-vision-2030-de-l-arabie-saoudite-a-chang%C3%A9-d%C3%A9finitivement-les-r%C3%A8gles-d-entr%C3%A9e-sur-le-marc69c1902a21bf88de83df3556Mon, 23 Mar 2026 19:18:23 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/accords-de-co-promotion-au-mena-comment-acc%C3%A9der-%C3%A0-une-force-de-vente-%C3%A9tablie-sans-en-cr%C3%A9er-une-de69c18a66045e3cfb799508d4Mon, 23 Mar 2026 18:48:31 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/co-promotion-agreements-in-mena-how-to-access-an-established-sales-force-without-building-one-from69c1892e69ed8cb882ab28a1Mon, 23 Mar 2026 18:45:48 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/joint-ventures-in-mena-pharma-the-governance-decisions-that-determine-whether-your-jv-thrives-or-fa69c187e1574473e63633a094Mon, 23 Mar 2026 18:38:48 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/coentreprises-pharmaceutiques-au-mena-les-d%C3%A9cisions-de-gouvernance-qui-d%C3%A9terminent-si-votre-jv-pro69c1869b8fe05188d48a4e0dMon, 23 Mar 2026 18:35:02 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/the-european-pharmaceutical-market-a-strategic-window-for-mena-companies-seeking-innovation-access69c1846ef35199f199d4612eMon, 23 Mar 2026 18:23:57 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/le-march%C3%A9-pharmaceutique-europ%C3%A9en-une-fen%C3%AAtre-strat%C3%A9gique-pour-les-entreprises-mena-cherchant-l-ac69c18334adda444fefaeda85Mon, 23 Mar 2026 18:20:13 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/pourquoi-l-am%C3%A9rique-du-nord-reste-le-hub-mondial-de-l-innovation-pharmaceutique-et-ce-que-cela-sign69c17de78f0e652aaa2c15f3Mon, 23 Mar 2026 18:03:41 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/why-north-america-remains-the-world-s-pharma-innovation-hub-and-what-that-means-for-global-partners69c17f76638c348fb123cd3cMon, 23 Mar 2026 18:03:20 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/le-mod%C3%A8le-de-partenariat-pharmaceutique-bidirectionnel-comment-les-acteurs-mena-acc%C3%A8dent-%C3%A0-l-innov69c17442adda444fefaeb697Mon, 23 Mar 2026 17:30:49 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/the-bidirectional-pharma-partnership-model-how-mena-players-access-western-innovation69c1763a5d51d790afeea31eMon, 23 Mar 2026 17:30:42 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/why-saudi-vision-2030-has-permanently-changed-the-rules-of-mena-pharmaceutical-market-entry69c18b508fe05188d48a59ebMon, 23 Mar 2026 04:00:00 GMTSarra Regraguihttps://www.nexuspharmalink.com/en/post/why-70-of-pharma-expansions-into-mena-fail-and-how-to-avoid-it69bb141f79de39203f138fa6Wed, 18 Mar 2026 21:12:25 GMTSarra Regraguihttps://www.nexuspharmalink.com/post/pourquoi-70-des-expansions-pharma-vers-le-mena-%C3%A9chouent-et-comment-l-%C3%A9viter69bb10ff392d3386b9258de3Wed, 18 Mar 2026 21:07:27 GMTSarra Regragui